Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 2;79(1):191–198.e3. doi: 10.1016/j.molcel.2020.06.008

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Expression of L240F TUBB Confers Resistance to Rigosertib_pharm

(A) Log₂ enrichment of K562 cells expressing L240F TUBB or an empty construct after treatment with rigosertib_pharm or ON01500 in internally controlled growth assays. Enrichment was measured as the ratio of mCherry-positive to mCherry-negative cells, e = fraction(mCh⁺) / fraction(mCh⁻), by flow cytometry, calculated relative to the first time point. Relative enrichment for each time point was normalized to that of DMSO-treated control cells. Data represent mean and individual measurements of replicate treatments (n = 2).

(B) Cumulative cell doublings of L240F TUBB-transduced or non-transduced K562 subpopulations treated with rigosertib_pharm or ON01500. Cumulative doublings were calculated from measurements of cell numbers and the fractions of mCherry-positive (L240F TUBB-transduced) and mCherry-negative cells (non-transduced) in the population. Data represent mean and individual measurements of replicate treatments (n = 2). Traces for DMSO-treated cells are identical in both panels in (B).